Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Diamanti, Daniela ^a   Mori, Elisa ^a   Incarnato, Danny ^b   Malusa, Federico ^a   Fondelli, Costanza ^a   Magnoni, Letizia ^a   Pollio, Giuseppe ^a  

^a Siena Biotech SpA   (Italy)

^b Human Genetics Foundation (HuGeF)   (Italy)

Author keywords

Blood; Gene expression; Huntington disease; R6 2

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BRAIN DEGENERATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DNA SYNTHESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HEART CONTRACTION; HUNTINGTON CHOREA; MALE; MICROARRAY ANALYSIS; MOUSE; MUSCLE CONTRACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

MUS; MUS MUSCULUS;

EID: 84928641662     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-28     Document Type: Article

References (61)

1. Roos RAC. Huntington's disease: a clinical review. Orphanet J Rare Dis 2010, 5(1):40.
2. Soulet D, Cicchetti F. The role of immunity in Huntington's disease. Mol Psychiatry 2011, 16(9):889-902.
3. Aziz NA, Swaab DF, Pijl H, Roos RAC. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007, 18(3-4):223-251.
4. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010, 90(3):905-981.
5. Kazantsev AG, Hersch SM. Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 2007, 83(4):249-259.
6. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease?. Neurobiol Dis 2012, 45(1):83-98.
7. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, Clark TW, Bouzou B, Cha JHJ. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008, 28(42):10720-10733.
8. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000, 97(12):6763-6768.
9. Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2009, 2(3-4):123-129.
10. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 2009, 1792(6):506-520.
11. Crook ZR, Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69(3):423-435.
12. Vonsattel JPG. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115(1):55-69.
13. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies S, Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
14. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, Court FA, Morton AJ. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004, 20(11):3092-3114.
15. Strand AD, Aragaki AK, Baquet ZC, Hodges A, Cunningham P, Holmans P, Jones KR, Jones L, Kooperberg C, Olson JM. Conservation of regional gene expression in mouse and human brain. PLoS Genet 2007, 3(4):e59.
16. Diamanti D, Lahiri N, Tarditi A, Magnoni L, Fondelli C, Morena E, Malusa F, Pollio G, Diodato E, Tripepi G, Tabrizi SJ, Caricasole A, Mori E. Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice. Journal of Huntington's Disease 2013, 2(2):185-200.
17. Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009, 4(11):e8025.
18. van der Burg JMM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009, 8(8):765-774.
19. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008, 205(8):1869-1877.
20. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A 2005, 102(31):11023-11028.
21. Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Régulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A 2007, 104(36):14424-14429.
22. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci 2008, 39(1):1-7.
23. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007, 6(7):2833-2840.
24. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129(Pt 4):877-886.
25. Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev 2011, 63(12):965-975.
26. Francis K, van Beek J, Canova C, Neal JW, Gasque P. Innate immunity and brain inflammation: the key role of complement. Expert Rev Mol Med 2003, 5(15):1-19.
27. Nayak A, Ansar R, Verma SK, Bonifati DM, Kishore U. Huntington's disease: an immune perspective. Neurol Res Int 2011, 2011:563784.
28. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999, 159(2):362-376.
29. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Björkqvist M. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr 2011, 3. RRN1231.
30. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010, 9(1):43-56.
31. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007, 25(11):1265-1275.
32. Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008, 2008:418765.
33. Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 2009, 18(6):1006-1016.
34. Valenza M, Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci 2011, 34(9):474-486.
35. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. Prog Neurobiol 2006, 80(4):165-176.
36. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I. Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 2010, 4(1):17-23.
37. Zündorf G, Reiser G. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal 2011, 14(7):1275-1288.
38. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 2004, 322(4):1310-1317.
39. Jin YN, Johnson GVW. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. Journal of bioenergetics and biomembranes 2010, 42(3):199-205.
40. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008, 283(9):5780-5789.
41. Damiano M, Galvan L, Déglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010, 1802(1):52-61.
42. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. Journal of molecular and cellular cardiology 2001, 33(6):1065-1089.
43. Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. Journal of medical genetics 1992, 29(12):911-914.
44. Wood NI, Sawiak SJ, Buonincontri G, Niu Y, Kane AD, Carpenter AT, Giussani DA, Morton AJ. Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease. Journal of Huntington's Disease 2012, 1(1):57-64.
45. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007, 25(2):297-308.
46. Aziz H, Zaas A, Ginsburg GS. Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Medicine 2007, 1(3-4):105-112.
47. Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 2007, 13(10):422-432.
48. Peng X, Wood CL, Blalock EM, Chen KC, Landfield PW, Stromberg AJ. Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinforma 2003, 4:26.
49. Larkin PB, Muchowski PJ. Genetic deficiency of complement component 3 does not alter disease progression in a mouse model of Huntington's disease. J Huntingtons Dis 2012, 1(1):107-118.
50. She P, Zhang Z, Marchionini D, Diaz WC, Jetton TJ, Kimball SR, Vary TC, Lang CH, Lynch CJ. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. Am J Physiol Endocrinol Metab 2011, 301(1):E49-E61.
51. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002, 11(17):1911-1926.
52. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005, 14(13):1863-1876.
53. Greco 3J, Pollins AC, Boone BE, Levy SE, Nanney LB. A microarray analysis of temporal gene expression profiles in thermally injured human skin. Burns 2010, 36(2):192-204.
54. Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Alterations in the mouse and human proteome caused by Huntington's disease. Mol Cell Proteomics 2002, 1(5):366-375.
55. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RLM, Olson JM, Jones L, Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15(6):965-977.
56. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
57. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix genechip probe level data. Nucleic Acids Res 2003, 31(4):e15.
58. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193.
59. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. article 3.
60. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545-15550.
61. Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 2013, 29(14):1830-1831.